Marlous Hoogstraat

List of Publications by Year
in descending order

16 papers	898 citations	840776 11 h-index	940533 16 g-index
16 all docs	16 docs citations	16 times ranked	2504 citing authors

#	Article	IF	Citations
1	Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments. Clinical Cancer Research, 2022, 28, 960-971.	7.0	4
2	Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance. Npj Breast Cancer, 2022, 8, 60.	5.2	11
3	Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. Nature Genetics, 2022, 54, 850-860.	21.4	34
4	Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence. Cancer Discovery, 2022, 12, 2074-2097.	9.4	22
5	A case-control study to identify molecular risk factors for local recurrence in young breast cancer patients. Radiotherapy and Oncology, 2021, 156, 127-135.	0.6	8
6	An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nature Cell Biology, 2021, 23, 1023-1034.	10.3	72
7	The molecular genetic make-up of male breast cancer. Endocrine-Related Cancer, 2019, 26, 779-794.	3.1	27
8	Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1Î² in tumor-associated macrophages. OncoImmunology, 2017, 6, e1334744.	4.6	81
9	RUBIC identifies driver genes by detecting recurrent DNA copy number breaks. Nature Communications, 2016, 7, 12159.	12.8	13
10	TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2. Oncotarget, 2016, 7, 58435-58444.	1.8	8
11	Robust BRCA1â€like classification of copy number profiles of samples repeated across different datasets and platforms. Molecular Oncology, 2015, 9, 1274-1286.	4.6	29
12	Detailed imaging and genetic analysis reveal a secondary <scp>BRAF^L</scp>^{505H} resistance mutation and extensive intrapatient heterogeneity in metastatic <scp>BRAF</scp> mutant melanoma patients treated with vemurafenib. Pigment Cell and Melanoma Research, 2015, 28, 318-323.	3.3	20
13	Simultaneous Detection of Clinically Relevant Mutations and Amplifications for Routine Cancer Pathology. Journal of Molecular Diagnostics, 2015, 17, 10-18.	2.8	35
14	Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes. PLoS ONE, 2014, 9, e103988.	2.5	319
15	Targeted next-generation sequencing: AÂnovel diagnostic tool for primary immunodeficiencies. Journal of Allergy and Clinical Immunology, 2014, 133, 529-534.e1.	2.9	143
16	Genomic and transcriptomic plasticity in treatment-naÃ¯ve ovarian cancer. Genome Research, 2014, 24, 200-211.	5.5	72